Innoviva Other Non-Current Liabilities 2010-2024 | INVA

Innoviva other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Innoviva Annual Other Non-Current Liabilities
(Millions of US $)
2024 $118
2023 $84
2022 $81
2021 $0
2020 $0
2019 $0
2018 $1
2017 $1
2016 $1
2015 $2
2014 $2
2013 $0
2012 $0
2011 $0
2010 $0
2009 $0
Innoviva Quarterly Other Non-Current Liabilities
(Millions of US $)
2024-12-31 $118
2024-09-30 $83
2024-06-30 $84
2024-03-31 $83
2023-12-31 $84
2023-09-30 $79
2023-06-30 $79
2023-03-31 $80
2022-12-31 $81
2022-09-30 $78
2022-06-30
2022-03-31
2021-12-31
2021-09-30 $0
2021-06-30 $0
2021-03-31 $0
2020-12-31 $0
2020-09-30 $0
2020-06-30 $0
2020-03-31 $0
2019-12-31 $0
2019-09-30 $0
2019-06-30 $0
2019-03-31 $0
2018-12-31 $1
2018-09-30 $1
2018-06-30 $1
2018-03-31 $1
2017-12-31 $1
2017-09-30 $1
2017-06-30 $1
2017-03-31 $1
2016-12-31 $1
2016-09-30 $2
2016-06-30 $2
2016-03-31 $2
2015-12-31 $2
2015-09-30 $2
2015-06-30 $2
2015-03-31 $2
2014-12-31 $2
2014-09-30 $2
2014-06-30 $1
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31 $0
2009-12-31 $0
2009-09-30 $0
2009-06-30 $1
2009-03-31 $1
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.132B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $835.717B 67.80
Novo Nordisk (NVO) Denmark $406.526B 27.53
Johnson & Johnson (JNJ) United States $394.223B 16.39
AbbVie (ABBV) United States $360.274B 20.17
Roche Holding AG (RHHBY) Switzerland $264.748B 0.00
Merck (MRK) United States $230.880B 11.95
Novartis AG (NVS) Switzerland $223.246B 13.98
Pfizer (PFE) United States $151.025B 8.57
Sanofi (SNY) $136.409B 12.92
Bayer (BAYRY) Germany $23.028B 3.69